Home > Rheumatology > ACR 2020 > Spondyloarthritis – The Beat Goes On > Resolution of dactylitis or enthesitis is associated with improvements in joint and skin symptoms

Resolution of dactylitis or enthesitis is associated with improvements in joint and skin symptoms

Presented By
Prof. Dennis McGonagle, University of Leeds, UK
Conference
ACR 2020
Trial
Phase 3, DISCOVER-1 & -2
An analysis of the DISCOVER-1 and DISCOVER-2 trials revealed that guselkumab led to a significant resolution of dactylitis and enthesitis in patients with active psoriatic arthritis. Resolution of these key symptoms was associated with ACR20/50/70 and PASI75/90 response. The selective IL-23 blocker guselkumab demonstrated efficacy in patients with active psoriatic arthritis (PsA) in the two phase 3 trials DISCOVER-1 (NCT03162796) and DISCOVER‑2 (NCT03158285) [1]. Dactylitis and enthesitis are both key PsA clinical manifestations that can be difficult to treat and increase the disease burden. In a pooled analysis of the DISCOVER-1 and -2 trials including 1,100 patients, relationships between improvements in dactylitis or enthesitis and other PsA domains in patients with dac...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on